uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data #uniQure #Buy…

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 #uniQure #Bullish #NearTerm #Catalysts #Breakthrough…

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting #uniQure #AMT130 #Progresses #FDA #Meeting

UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington’s Disease Treatment

As of this writing, UniQure N.V.’s stock price has surged 35.89% to $12.79 per share after…